US7465715B2 - Method for treatment of multiple sclerosis - Google Patents

Method for treatment of multiple sclerosis Download PDF

Info

Publication number
US7465715B2
US7465715B2 US10/521,193 US52119305A US7465715B2 US 7465715 B2 US7465715 B2 US 7465715B2 US 52119305 A US52119305 A US 52119305A US 7465715 B2 US7465715 B2 US 7465715B2
Authority
US
United States
Prior art keywords
alkyl
amino
aminoalkyl
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/521,193
Other languages
English (en)
Other versions
US20060142237A1 (en
Inventor
Pnina Fishman
Sara Bar Yehuda
Lea Madi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Priority to US10/521,193 priority Critical patent/US7465715B2/en
Publication of US20060142237A1 publication Critical patent/US20060142237A1/en
Application granted granted Critical
Publication of US7465715B2 publication Critical patent/US7465715B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • This invention relates to compounds and methods useful in the treatment of multiple sclerosis.
  • MS Multiple sclerosis
  • CNS central nervous system
  • MBP myelin basic protein
  • EAE Experimental autoimmune encephalomyelitis
  • Adenosine receptors are classified into four major classes: A1, A2a, A2b and A3.
  • A3 adenosine receptors belong to the family of the G i -protein associated cell surface receptors. Receptor activation leads to its internalization and the subsequent inhibition of adenylyl cyclase activity, cAMP formation and protein kinase A (PKA) expression, resulting in the initiation of various signaling pathways (1,2) .
  • PKA contains a catalytic subunit PKAc which dissociates from the parent molecule upon activation with cAMP.
  • U.S. Pat. No. 5,506,214 (Beutler) discloses treatment of patients having MS with therapeutic agents containing substituted adenine derivatives such as 2-chloro-2′-deoxyadenosine (CdA). Treatment with CdA was shown to markedly ameliorate the disease condition.
  • CdA was found to be a putative partial agonist at A1 receptors, as described in Siddiqi, S. M. et al, (1995) J. Med. Chem. 38:1174-1188.
  • the K i values of CdA for the various adenosine receptors were 7.4 ⁇ M at the A1 receptor, 20 ⁇ M at the A2a receptor and 207 ⁇ M at the A3 receptor.
  • the present invention is based on the surprising finding that administration of A3 adenosine receptor agonist (A3RAg) alleviates symptoms of multiple sclerosis.
  • A3RAg A3 adenosine receptor agonist
  • the present invention concerns, by one embodiment, a method for the treatment of multiple sclerosis (MS) in a human subject, comprising administering to an individual in need of such treatment an effective amount of an A3RAg.
  • MS multiple sclerosis
  • MS multiple sclerosis
  • RRMS relapsing/remitting
  • SPMS secondary progressive
  • PRMS progressive relapsing
  • PPMS primary progressive
  • treatment refers to any improvement in the clinical symptoms of the disease, and/or a reduction in the rate of deterioration or the relapse rate of the MS patient, as well as any improvement in the well being of the patients.
  • an improvement may be manifested by one or more of the following: decrease in muscle weakness, decrease in muscle spasms, reduction of spasticity, improvement of balance and improvement in memory.
  • A3RAg adenosine A3 receptor agonist in the context of the present invention refers to any molecule capable of specifically binding to the adenosine A3 receptor (“A3R”), thereby fully or partially activating said receptor.
  • A3RAg is thus a molecule that exerts its prime effect through the binding and activation of the A3R. This means that at the doses it is being administered it essentially binds to and activates only the A3R.
  • an A3RAg has a binding affinity (K i ) to the human adenosine A3 receptor in the range of less than 100 nM, typically less than 50 nM, preferably less than 20 nM, more preferably less than 10 nM and ideally less than 5 nM.
  • Ki the lower the Ki, the lower the dose of the A3RAg (that may be used) that will be effective in activating the A3R and thus achieving a therapeutic effect.
  • A3RAgs that have a K i to the human A3R of less than 2 nM and even less than 1 nM may be preferred.
  • A3RAgs can also interact with and activate other receptors with lower affinities (namely a higher Ki).
  • a molecule will be considered an A3RAg in the context of the invention (namely a molecule that exerts its prime effect through the binding and activation A3R) if its affinity to the A3R is at least 3 times (i.e. its Ki to the A3R is at least 3 times lower), preferably 10 times, desirably 20 times and most preferably at least 50 times larger than the affinity to any other of the adenosine receptors (i.e. A1, A2a and A2b).
  • the affinity of an A3RAg to the human A3R as well as its relative affinity to the other human adenosine receptors can be determined by a number of assays, such as a binding assay.
  • assays include providing membranes or cells having the receptor and measuring the ability of the A3RAg to displace a bound radioactive agonist; utilizing cells that display the respective human adenosine receptor and measuring, in a functional assay, the ability of the A3RAg to activate or deactivate, as the case may be, downstream signaling events such as the effect on adenylate cyclase measured through increase or decrease of the cAMP level; etc.
  • an A3RAg is thus preferably administered at a dose such that the blood level that will be attained will give rise to essentially only A3R activation.
  • the A3RAg is a compound that exerts its prime effect through the binding and activation A3R and is a purine derivative falling within the scope of the general formula (I):
  • R 5 is selected from the group consisting of heteroaryl-NR a —C(Z)—, heteroaryl-C(Z)—, alkaryl-NR a —C(Z)—, alkaryl-C(Z)—, aryl-NR—C(Z)— and aryl-C(Z)—; Z representing an oxygen, sulfor or imine; or a physiologically acceptable salt of the above compound.
  • the A3RAg is a nucleoside derivative of the general formula (IV):
  • non-cyclic carbohydrate groups e.g. alkyl, alkenyl, alkynyl, alkoxy, aralkyl, alkaryl, alkylamine, etc
  • the non-cyclic carbohydrate groups are either branched or unbranched, preferably containing from one or two to twelve carbon atoms.
  • physiologically acceptable salts of the compounds employed by the present invention it is meant any non-toxic alkali metal, alkaline earth metal, and ammonium salt commonly used in the pharmaceutical industry, including the sodium, potassium, lithium, calcium, magnesium, barium ammonium and protamine zinc salts, which are prepared by methods known in the art.
  • the term also includes non-toxic acid addition salts, which are generally prepared by reacting the compounds of this invention with a suitable organic or inorganic acid.
  • the acid addition salts are those which retain the biological effectiveness and qualitative properties of the free bases and which are not toxic or otherwise undesirable. Examples include, inter alia, acids derived from mineral acids, hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, metaphosphoric and the like.
  • Organic acids include, inter alia, tartaric, acetic, propionic, citric, malic, malonic, lactic, fumaric, benzoic, cinnamic, mandelic, glycolic, gluconic, pyruvic, succinic salicylic and arylsulphonic, e.g. p-toluenesulphonic, acids.
  • A3RAg which may be employed according to general formula (IV) of the present invention include, without being limited thereto, N 6 -2-(4-aminophenyl)ethyladenosine (APNEA), N 6 -(4-amino-3-iodobenzyl) adenosine-5′-(N-methyluronanide) (AB-MECA), N 6 -(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA) and 2-chloro-N 6 -(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA).
  • APIA N 6 -2-(4-aminophenyl)ethyladenosine
  • AB-MECA N 6 -(4-amino-3-iodobenzyl) adenosine-5′-(N-methyluronanide)
  • the A3RAg may be an oxide derivative of adenosine, such as N 6 -benzyladenosine-5′-N-alkyluronamide-N 1 -oxide or N 6 -benzyladenosine-5′-N-dialkyluro wherein the 2-purine position may be substituted with an alkoxy, amino, alkenyl, alkynyl or halogen.
  • adenosine such as N 6 -benzyladenosine-5′-N-alkyluronamide-N 1 -oxide or N 6 -benzyladenosine-5′-N-dialkyluro wherein the 2-purine position may be substituted with an alkoxy, amino, alkenyl, alkynyl or halogen.
  • the administration of said A3RAg to a patient may be together with a pharmaceutically acceptable carrier.
  • the carrier is one that is acceptable for oral administration.
  • pharmaceutically acceptable carrier any one of inert, non-toxic materials, which do not react with the A3RAg and which can be added to formulations as diluents or carriers or to give form or consistency to the formulation.
  • An oral formulation may be in the form of a pill, capsule, in the form of a syrup, an aromatic powder, and other various forms.
  • the carrier is selected at times based on the desired form of the formulation.
  • the carrier may also at times have the effect of the improving the delivery or penetration of the active ingredient to the target tissue, for improving the stability of the drug, for slowing clearance rates, for imparting slow release properties, for reducing undesired side effects etc.
  • the carrier may also be a substance that stabilizes the formulation (e.g.
  • the carriers may be any of those conventionally used and is limited only by chemical-physical considerations, such as solubility and lack of reactivity with the A3RAg, and by the route of administration.
  • the carrier may include additives, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
  • the carrier may be an adjuvant, which, by definition are substances affecting the action of the active ingredient in a predictable way.
  • Typical examples of carriers include (a) liquid solutions, where an effective amount of the active substance is dissolved in diluents, such as water, saline, natural juices, alcohols, syrups, etc.; (b) capsules (e.g. the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers), tablets, lozenges (wherein the active substance is in a flavor, such as sucrose and acacia or tragacanth or the active substance is in an inert base, such as gelatin and glycerin), and troches, each containing a predetermined amount of the A3RAg as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; (e) suitable emulsions; (f) liposome formulation; and others.
  • diluents such as water, saline, natural juices, alcohols, syrups, etc.
  • capsules e.
  • an effective amount in the context of the present invention refers to an amount of A3RAg which results in neuralgic protection of the patient from the pathological symptoms of MS.
  • the “effective amount” can be readily determined, in accordance with the invention, by administering to a plurality of tested subjects various amounts of the A3RAg and then plotting the physiological response (for example an integrated “MS index” combining several of the therapeutically beneficial effects) as a function of the amount.
  • the effective amount may also be determined, at times, through experiments performed in appropriate animal models and then extrapolating to human beings using one of a plurality of conversion methods; or by measuring the plasma concentration or the area under the curve (AUC) of the plasma concentration over time and calculating the effective dose so as to yield a comparable plasma concentration or AUC.
  • the effective amount may depend on a variety of factors such as mode of administration (for example, oral administration may require a higher dose to achieve a given plasma level or AUC than an intravenous administration); the age, weight, body surface area, gender, health condition and genetic factors of the subject; other administered drugs; etc.
  • dosages are indicated in weight/Kg, meaning weight of administered A3RAg (e.g. IB-MECA or Cl-IB-MECA) per kilogram of body weight of the treated subject in each administration.
  • weight/Kg and microgram/Kg denote, respectively, milligrams of administered agent and micrograms of administered agent per kilogram of body weight of the treated subject.
  • mice the effective amount is typically less than about 1000 and preferably less than about 500 microgram/Kg.
  • a typical dose would be in the range of about 1 microgram/Kg to about 200 microgram/Kg, with a preferred dose being in the range of about 5 microgram/Kg to about 150 microgram/Kg.
  • the corresponding effective amount in a human will be a human equivalent amount to that observed in mice, which may be determined in a manner as explained bellow.
  • human equivalent refers to the dose that produces in human the same effect as featured when a dose of 0.001-1 mg/Kg of an A3RAg is administered to a mouse or a rat. As known, this dose depends and may be determined on the basis of a number of parameters such as body mass, body surface area, absorption rate of the active agent, clearance rate of the agent, rate of metabolism and others.
  • the human equivalent may be calculated based on a number of conversion criteria as explained bellow; or may be a dose such that either the plasma level will be similar to that in a mouse following administration at a dose as specified above; or a dose that yields a total exposure (namely area under the curve—AUC—of the plasma level of said agent as a function of time) that is similar to that in mice at the specified dose range.
  • Rat (150 g) to Man (70 Kg) is 1/7 the rat dose. This means that, for example, 0.001-1 mg/Kg in rats equals to about 0.14-140 microgram/Kg in humans. Assuming an average human weight of 70 Kg, this would translate into an absolute dosage for humans of about 0.01 to about 10 mg.
  • the amounts equivalent to 0.001-1 mg/Kg in rats for humans are 0.16-64 ⁇ g/Kg; namely an absolute dose for a human weighing about 70 Kg of about 0.011 to about 11 mg, similar to the range indicated in Conversion I.
  • Another alternative for conversion is by setting the dose to yield the same plasma level or AUC as that achieved following administration to an animal. For example, based on measurement made in mice following oral administration of IB-MECA and based on such measurements made in humans in a clinical study in which IB-MECA was given to healthy male volunteers it can be concluded that a dose of 1 microgram/Kg-1,000 microgram/KG in mice is equivalent to a human dose of about 0.14-140 microgram/Kg, namely a total dose for a 70 Kg individual of 0.01-10 mg.
  • a pharmaceutical composition for the treatment of multiple sclerosis that comprises an effective amount of an A3RAg as defined above and a pharmaceutically acceptable carrier; as well as the use of said A3RAg for the preparation of a pharmaceutical composition for administration to a subject suffering from multiple sclerosis and being in need of a neuralgic protective treatment.
  • the effective amount in the pharmaceutical composition will depend on the intended therapeutic regimen and the desired therapeutic dose. By way of example, where the dose is 1 mg per day and the. desired administration regimen is once daily, the amount of active agent in the pharmaceutical composition will be 1 mg. In cases where it is intended to administer this daily dose in 2 daily administrations, the amount of the active agent in the pharmaceutical composition will be 0.5 mg.
  • FIG. 1 is a graph illustrating the clinical symptoms of rats suffering from EAE as a function of time, which were treated ( ⁇ ) or not treated ( ⁇ ) with the A3RAg IB-MECA (CF101).
  • IB-MECA produced as a clinical grade material under clinical good manufacturing practice (cGMP) conditions by Albany Molecular Research, Albany, New York, USA on behalf of Can-Fite BioPharma, Ltd., Israel (this material is designated as CF101).
  • cGMP clinical good manufacturing practice
  • a stock solution of 10 ⁇ M was prepared in DMSO and further dilutions were made in RPMI medium.
  • EAE was induced by intradermal injection at the base of the tail of female Lewis rats (8 weeks old) with an emulsion consisting of the following for each rat: 100 ⁇ g myelin basic protein (MBP) from guinea pig (M2295; Sigma), 0.1 ml Complete Freund's adjuvant (CFA; F5506, Sigma), and 0.2 mg of Mycobacterium tuberculosis H37 Ra ( M. tuberculosis , 3114, Difco).
  • MBP myelin basic protein
  • CFA Complete Freund's adjuvant
  • the emulsion was injected in two halves into the medial footpad of each hind limb of the rats.
  • the immunized rats developed acute monophasic EAE within 10 days after immunization that lasted for 5 days.
  • a remarkably low clinical score in the CF101 treated group in comparison to the control group was noted.
  • the difference in the maximal clinical score between the CF101 and the control groups was significant with P ⁇ 0.01 using the Student's t test, and the severity of the disease in the treated group was significantly reduced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Sewing Machines And Sewing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
US10/521,193 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis Expired - Fee Related US7465715B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/521,193 US7465715B2 (en) 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53271203P 2003-12-29 2003-12-29
US10/521,193 US7465715B2 (en) 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis
PCT/IL2004/001160 WO2005063246A1 (en) 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
US20060142237A1 US20060142237A1 (en) 2006-06-29
US7465715B2 true US7465715B2 (en) 2008-12-16

Family

ID=34738826

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/521,193 Expired - Fee Related US7465715B2 (en) 2003-12-29 2004-12-23 Method for treatment of multiple sclerosis

Country Status (10)

Country Link
US (1) US7465715B2 (de)
EP (1) EP1699459B1 (de)
JP (1) JP2007517019A (de)
CN (1) CN100423723C (de)
AT (1) ATE363907T1 (de)
DE (1) DE602004006895T2 (de)
DK (1) DK1699459T3 (de)
ES (1) ES2287804T3 (de)
PL (1) PL1699459T3 (de)
WO (1) WO2005063246A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US20150018299A1 (en) * 2012-01-23 2015-01-15 Can-Fite Biopharma Ltd. Treatment of liver conditions

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1817079B1 (de) 2004-12-02 2008-07-30 Can-Fite Biopharma Ltd. Behandlung von entzündungen
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ATE502640T1 (de) 2006-01-26 2011-04-15 Us Gov Health & Human Serv Allosterische a3-adenosin-rezeptormodulatoren
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
JP5373599B2 (ja) * 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
EP2137202B1 (de) 2007-03-14 2017-06-21 Can-Fite Biopharma Ltd. Verfahren zur herstellung von ib-meca
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
EP3124970A1 (de) * 2011-04-22 2017-02-01 Kyoto University Verwendung des basischen myelinproteins als neuartiger genetischer faktor für rheumatoide arthritis
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201892008A1 (ru) * 2016-04-21 2019-06-28 Астросайт Фармасьютикалс, Инк. Соединения и способы лечения неврологических и сердечно-сосудистых состояний

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5506214A (en) 1986-02-03 1996-04-09 The Scripps Research Institute Use of substituted adenine derivatives for treating multiple sclerosis
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US20020094974A1 (en) 1999-12-02 2002-07-18 Castelhano Arlindo L. Compounds specific to adenosine A3 receptor and uses thereof
US6762170B1 (en) 1998-01-31 2004-07-13 Smithklinebeecham Corporation 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO2004058791A2 (en) * 2002-12-30 2004-07-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506214A (en) 1986-02-03 1996-04-09 The Scripps Research Institute Use of substituted adenine derivatives for treating multiple sclerosis
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US6762170B1 (en) 1998-01-31 2004-07-13 Smithklinebeecham Corporation 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US20020094974A1 (en) 1999-12-02 2002-07-18 Castelhano Arlindo L. Compounds specific to adenosine A3 receptor and uses thereof
WO2004058791A2 (en) * 2002-12-30 2004-07-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gold et al., "Animal Models for Autoimmune Demyelinating Disorders of the Nervous System," Molecular Medicine Today, 6, 88-91 (Feb. 2000). *
Link et al., "Rat Models as Tool to Develop New Immunotherapies," Immunological Reviews, 184, 117-128 (2001). *
Mix et al., "Gene-Expression Profiling of Experimental Autoimmune Encephalitis," Neurochemical Research, 27(10), 1157-1163 (Oct. 2002). *
Siddiqi, S.M. et al., "Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors", J. Med. Chem, (1995), vol. 38, pp. 1174-1188.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US20120134945A1 (en) * 2009-07-21 2012-05-31 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US9199102B2 (en) * 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US9668959B2 (en) 2009-07-21 2017-06-06 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US20150018299A1 (en) * 2012-01-23 2015-01-15 Can-Fite Biopharma Ltd. Treatment of liver conditions

Also Published As

Publication number Publication date
ATE363907T1 (de) 2007-06-15
PL1699459T3 (pl) 2007-12-31
WO2005063246A1 (en) 2005-07-14
US20060142237A1 (en) 2006-06-29
DK1699459T3 (da) 2007-10-08
CN100423723C (zh) 2008-10-08
DE602004006895D1 (de) 2007-07-19
EP1699459B1 (de) 2007-06-06
JP2007517019A (ja) 2007-06-28
DE602004006895T2 (de) 2008-01-31
CN1901915A (zh) 2007-01-24
ES2287804T3 (es) 2007-12-16
EP1699459A1 (de) 2006-09-13

Similar Documents

Publication Publication Date Title
US7465715B2 (en) Method for treatment of multiple sclerosis
US10265337B2 (en) Use of A3 adenosine receptor agonist in osteoarthritis treatment
EP1778239B1 (de) Adenosin-a3-rezeptoragonisten zur behandlung von trockenem auge, einschliesslich sjögren-syndrom
US7825102B2 (en) Treatment of dry eye conditions
PT1171137E (pt) Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
US20080051364A1 (en) Therapeutic Treatment of Accelerated Bone Resorption
EP1817079B1 (de) Behandlung von entzündungen
US11291681B2 (en) Method for treating fibrotic liver tissue using Cl-IB-MECA
AU2005302090A1 (en) Therapeutic treatment of accelerated bone resorption
US20080051365A1 (en) Treatment of Inflammation
US20130045943A1 (en) A3ar agonists for the treatment of uveitis
US20150216889A1 (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
US20050277615A1 (en) Pharmaceutical compositions having anti-inflammatory activity

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20121216